AstraZeneca’s experimental pill has shown promise in reducing “bad” cholesterol, raising expectations for more convenient alternatives in treatment options. AstraZenca is testing a once-daily PCSK9 ...

New data from the PURSUIT Phase IIb trial reveal AstraZeneca‘s investigational oral PCSK9 inhibitor, AZD0780, delivers ...

AstraZeneca Plc’s experimental cholesterol drug significantly reduced “bad” cholesterol in a mid-stage trial, boosting hopes ...

In a phase 2b study, treatment with a once-daily oral PCSK9 inhibitor added to statin therapy resulted in a more than 50% ...

AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol reduction when administered on top of ...

The highest dose of AstraZeneca’s small molecule halved levels of a type of “bad” cholesterol after 12 weeks, hitting the ...

AstraZeneca has revealed phase 2b results with its oral PCSK9 inhibitor AZD0780, including a more than 50% reduction in ...

Subscribe here to receive future editions. The race to develop more convenient versions of drugs that lower cholesterol is heating up after AstraZeneca released encouraging new data on an ...

AstraZeneca's executive vice president Sharon Barr said: “These new data reflect AZD0780’s ability to reduce LDL cholesterol in patients who need more options to manage their cholesterol and ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...